Advice
in the absence of a submission from the holder of the marketing authorisation:
talimogene laherparepvec (Imlygic®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- talimogene laherparepvec (Imlygic)
- SMC ID:
- 1248/17
- Indication:
- Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 May 2017